Abstract
6/2005
vol. 8
Inhaled corticosteroids and long acting β2-agonists in asthma and chronic obstructive pulmonary disease (COPD)
Przew Lek 2005; 6: 90-95
Online publish date: 2005/09/19
Agonists of β2 receptors are the most potent bronchial dilators. Available long-acting β2-agonists are widely used in the treatment of both bronchial asthma and COPD. However, administration of these drugs alone is rather disadvantageous because of the risk of tachyphylaxis. Other group of medicines used in the bronchial asthma and COPD are inhaled glucorticosteroids. They are the first choice drugs in asthma therapy and their effectiveness is well documented. If, however, they are ineffective is the
administered dose, its increase does not bring about desired effect. In such a situation addition of the
long-acting β2-agonists accelerate stabilization of the disease course. Recently, several papers were
published, positively assessing the use of such a combined therapy in COPD. An effect of both
components are considered additive and not simply summed up.
administered dose, its increase does not bring about desired effect. In such a situation addition of the
long-acting β2-agonists accelerate stabilization of the disease course. Recently, several papers were
published, positively assessing the use of such a combined therapy in COPD. An effect of both
components are considered additive and not simply summed up.
Keywords
inhaled corticosteroids, long-acting β2-agonists, asthma, COPD
Integrated with
